enGene Holdings: Compelling Early Data Bode Well For Their Near-Term Outlook

enGene Holdings (NASDAQ: ENGN ) is a biotech focused mainly on the development of gene therapies, with their first shot on goal being in specific forms of bladder cancer. Through the use of plasmid technology, the company hopes to demonstrate that non-viralI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due dili ...